Posts by: Maureen Newman

Maureen Newman

Maureen Newman is a senior Science and Research writer for Cystic Fibrosis News Today. Maureen is currently a PhD student studying biomedical engineering at University of Rochester, working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit's laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment.

May 22, 2015May 22, 2015

Protein Blocking Effectiveness of Vertex’s Experimental CF Therapy Lumacaftor Discovered

cystic fibrosis, News

Despite every effort to design a drug effective in helping cystic fibrosis patients with defective CFTR proteins, sometimes drugs are thwarted by mechanisms orchestrated by other proteins within cells. A ... Read more

May 19, 2015August 31, 2015

Vertex’s Orkambi Safe and Effective for Treating CF F508del Mutation

cystic fibrosis, News

Two Phase III clinical trials from Northwestern University’s Feinberg School of Medicine and Stanley Manne Children’s Research Institute at Ann Robert H. Lurie Children’s Hospital of Chicago tested a combination treatment ... Read more

May 13, 2015May 13, 2015

Vertex’s CF Therapy Orkambi Receives Positive Recommendation for FDA Approval

cystic fibrosis, News

After the Pulmonary-Allergy Drugs Advisory Committee (PADAC) met to discuss the approval of Orkambi, members of the committee voted 12 to 1 recommending Vertex Pharmaceuticals’ new treatment for cystic fibrosis ... Read more

May 11, 2015May 11, 2015

PADAC, FDA Meet to Discuss Vertex Pharmaceuticals’ Experimental CF Therapy

cystic fibrosis, News

The Food and Drug Administration (FDA) will be evaluating the new drug application (NDA) for Vertex Pharmaceutical’s Orkambi, indicated to treat cystic fibrosis in patients with the F508del mutation on ... Read more

April 28, 2015April 28, 2015

New Assay Could Help Researchers Discover Promising CF Therapeutics for ΔF508-CFTR

cystic fibrosis, News

Discovering new compounds to treat cystic fibrosis is now more feasible as a result of work in the collaborative laboratory of Dr. Aleksander Edelman at INSERM in France. The research ... Read more

April 13, 2015April 13, 2015

Clinical Study Details Pulmonary Function Improvement in 5 CF Patients Using AffloVest

cystic fibrosis, News

AffloVest, a wearable, self-contained oscillation vest device from International Biophysics that helps patients with Cystic Fibrosis breathe easier, was previously backed by numerous patient testimonies and is now proven in a ... Read more

March 23, 2015July 6, 2016

UK Adult Cystic Fibrosis Patient Population Predicted to Increase

cystic fibrosis, News

It is time to celebrate more birthdays. Patients with cystic fibrosis, an orphan disease affecting fewer than 200,000 individuals throughout the world, are experiencing an increase in longevity. Estimates from a ... Read more

March 20, 2015March 20, 2015

A New Study Method for P. aeruginosa May Accelerate CF Research

cystic fibrosis, News

Researchers are finding ways to better understand infection in cystic fibrosis, enabling research efforts that help discover treatments for patients. Dr. Marvin Whiteley at The University of Texas at Austin created a ... Read more

March 10, 2015March 10, 2015

Cystic Fibrosis Symptom Severity May be Influenced by Gene Clusters

cystic fibrosis, News

One size does not fit all when it comes to cystic fibrosis patients’ symptoms, despite the commonality of a mutated gene. Some patients endure severe life-long airway infections while others ... Read more

February 25, 2015February 25, 2015

CF Drug Developer Savara Meets Primary Endpoint for Treating MRSA in Phase 2 Trial

cystic fibrosis, News

A phase 2 trial from Savara Pharmaceuticals investigating its lead product AeroVanc to treat methicillin-resistant Staphylococcus aureus (MRSA) infections in cystic fibrosis patients met a key primary endpoint. Patients treated ... Read more